Palvanil (0.1-1000 nM; 0-300 min) leads to calcium increasment in HEK-293 intracellular[1].
Palvanil (1-10 nM; 5 min) treatment desensitizes TRPV1 to the effect of Capsaicin significantly[1].
Palvanil (subcutaneous injection; 1 or 10 mg/kg; once) treatment shows hypothermic effect[2].
Palvanil (intraperitoneal injection; 100 μL (15 nM) per mouse; once) treatment reduces Capsaicin-induced bronchoconstriction[2].
Palvanil (intravenous injection; 0.5, 0.75, and 1 mg/kg; once) treatment shows antinociceptive effects on Formalin-induced nocifensive behavior[2].
Palvanil (intravenous injection; 0.5, 0.75, and 1 mg/kg; once) treatment inhibits Carrageenan-induced inflammation[2].
Palvanil (intravenous injection; 0.5 and 1 mg/kg; once daily; 7 days) reduces mechanical allodynia and thermal hyperalgesia in spared nerve injury (SNI) mice[2].
References:
[1]. Luciano De Petrocellis, et al. N-palmitoyl-vanillamide (palvanil) is a non-pungent analogue of capsaicin with stronger desensitizing capability against the TRPV1 receptor and anti-hyperalgesic activity. Pharmacol Res. 2011 Apr;63(4):294-9.
[2]. Livio Luongo, et al. Palvanil, a non-pungent capsaicin analogue, inhibits inflammatory and neuropathic pain with little effects on bronchopulmonary function and body temperature. Pharmacol Res. 2012 Sep;66(3):243-50.